Mylan introduces Pristiq generic

PITTSBURGH — Mylan introduced Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a generic version of Pfizer's Pristiq Tablets, in the United States.

Desvenlafaxine is indicated for the treatment of a major depressive disorder. Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, had U.S. sales of approximately $853 million for the 12 months ending January 31, 2017, according to IMS Health.

As Drug Store News reported, Teva Pharmaceuticals also launched a generic version of Pristiq on March 1.

 Mylan offers a portfolio of approximately 7,500 marketed products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend.